(Q30240235)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

review article

1 reference

title

Treatment of soft tissue sarcoma: a focus on earlier stages (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Robert G. Maki

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Robin L Jones

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

author name string

Robert G Maki

2

1 reference

12 June 2017

Robin L Jones

3

1 reference

12 June 2017

language of work or name

English

0 references

publication date

1 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

issue

1s

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

13-21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

The effect of the setting of a positive surgical margin in soft tissue sarcoma

29 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Diagnosis and management of retroperitoneal soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Sarcoma: Olaratumab - really a breakthrough for soft-tissue sarcomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

Primary Adult Soft Tissue Sarcoma: Time-Dependent Influence of Prognostic Variables

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0499

21 January 2018

Identifiers

DOI

10.2217/FON-2016-0499

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27918202%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference